Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-22 02:43:43 Source:worldViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
You may also like
- Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
- Bride calls out wedding guest's 'disrespectful' RSVP: 'This is not how invitations work'
- He's out! Monty Panesar pulls stumps on his bid to become an MP for George Galloway's party as ex
- Boeing 737 catches fire and skids off the runway at a Senegal airport, injuring 10 people
- Analysis: Larson enters conversation with Verstappen as best drivers in the world
- Intruder tries to break into Drake's house one day after his security guard was shot outside
- Why we need more than a British Isa to move the dial on UK smaller companies
- EDEN CONFIDENTIAL: Pals mourn the king of Centre Court cool, Tim Henman's father
- Bichette has 4 hits, Berríos snaps 4